Royce A. Morrison

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

Kenneth Von Eschen, Royce A. Morrison, Madeleine Braun et al. · Human Vaccines · 2009 · 105 citations

Life Sciences, Immunology, Infectious Diseases +15

Concomitant oral and intravenous pharmacokinetics of trametinib, a <scp>MEK</scp> inhibitor, in subjects with solid tumours

Cathrine Leonowens, Carolyn Pendry, John W. Bauman et al. · British Journal of Clinical Pharmacology · 2014 · 46 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation

David A. Bershas, Danièle Ouellet, Donna Mamaril-Fishman et al. · Drug Metabolism and Disposition · 2013 · 45 citations

Medicine, Oncology, Pharmacology +15

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

Cathrine L. Denton, Elisabeth A. Minthorn, Stanley W. Carson et al. · The Journal of Clinical Pharmacology · 2013 · 38 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

May Y. K. Ho, Michael J. Morris, Jill Pirhalla et al. · Xenobiotica · 2013 · 27 citations

Pharmacy, Oncology, Pharmacology +16